Search
Publication of Simcere Pharmaceutical's "Daliresan" Phase III Clinical Data in China in Prestigious "Sleep" Journal
2025-08-26 /
Read about 0 minute
Author：小编
In a groundbreaking development, Daliresan has emerged as the first new-generation DORA class anti-insomnia drug in China to deliver positive results across both primary and key secondary endpoints in Phase III clinical trials. These trials have demonstrated that Daliresan not only significantly enhances sleep maintenance and accelerates the onset of sleep but also extends sleep duration, while maintaining a low incidence of morning sleepiness. This landmark achievement presents a novel and promising treatment option for insomnia patients in China.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
